Brian L. Pearlman

TL;DR: The C-WORTHY trial as mentioned in this paper was a randomized, open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin in patients with hepatitis C virus (HCV) genotype 1 infection with baseline characteristics of poor response.

TL;DR: Extending the treatment duration from 48 weeks to 72 weeks in genotype 1–infected patients with slow virologic response to peginterferon‐α2b and weight‐based ribavirin significantly improves SVR rates.

TL;DR: Salicylates should be considered in the differential diagnosis of an adult patient with acid-base abnormalities of uncertain cause, especially when there are concurrent neurologic symptoms, particularly in the elderly.

TL;DR: SOF/VEL/VOX is an effective regimen for virologic failures to G/P and ninety-four percent of subjects achieved sustained virology response with re-treatment, despite 90% of 31 subjects harboring nonstructural 5A inhibitor resistance-associated mutations at baseline.

TL;DR: Based on data from both viral kinetic and clinical studies, therapy prolongation in slow responders may be a reasonable strategy to improve response rates in these treatment-refractory patients.